GeneMind Biosciences reported that China’s NMPA registered its SURFSeq 5000 Dx high-throughput sequencer as a Category III medical device. The registration enables clinical deployment in China for DNA and RNA sequencing across oncology, inherited disease, reproductive health, and infectious disease applications. GeneMind said SURFSeq 5000 can generate up to 2.2 terabytes of data per run using two independent flow cells. The company noted the platform is not approved for clinical whole-genome sequencing under the current registration certificate. For molecular diagnostics developers, the NMPA step expands go-to-market ability for sequencing workflows and supports broader adoption of NGS platforms outside research-only settings.